Showing 1 - 16 results of 16 for search 'Andreas Trojan', query time: 0.07s Refine Results
  1. 1
    Response to Vemurafenib in Metastatic Triple-Negative Breast Cancer Harbouring a BRAF V600E Mutation: A Case Report and Electronically Captured Patient-Reported Outcome

    Response to Vemurafenib in Metastatic Triple-Negative Breast Cancer Harbouring a BRAF V600E Mutation: A Case Report and Electronically Captured Patient-Reported Outcome by Magdalena Pircher, Thomas Winder, Andreas Trojan

    Published 2021-03-01
    Get full text
    Article
  2. 2
    Consilium Smartphone App for Real-World Electronically Captured Patient-Reported Outcome Monitoring in Cancer Patients Undergoing anti-PD-L1-Directed Treatment

    Consilium Smartphone App for Real-World Electronically Captured Patient-Reported Outcome Monitoring in Cancer Patients Undergoing anti-PD-L1-Directed Treatment by Andreas Trojan, Urs Huber, Mathis Brauchbar, Ulf Petrausch

    Published 2020-05-01
    Get full text
    Article
  3. 3
    Interference of Herbal Medicine with Axitinib in Metastatic Renal Cell Cancer Treatment: A Case Study

    Interference of Herbal Medicine with Axitinib in Metastatic Renal Cell Cancer Treatment: A Case Study by Friederike Himmelreich, Alexander Jetter, Michael K. Kiessling, Yannick Kadvany, Andreas Trojan

    Published 2023-11-01
    Get full text
    Article
  4. 4
    Towards an early warning system for monitoring of cancer patients using hybrid interactive machine learning

    Towards an early warning system for monitoring of cancer patients using hybrid interactive machine learning by Andreas Trojan, Andreas Trojan, Emanuele Laurenzi, Stephan Jüngling, Sven Roth, Michael Kiessling, Ziad Atassi, Yannick Kadvany, Meinrad Mannhart, Christian Jackisch, Gerd Kullak-Ublick, Hans Friedrich Witschel

    Published 2024-08-01
    Get full text
    Article
  5. 5
    Effective response with bortezomib retreatment in relapsed multiple myeloma

    Effective response with bortezomib retreatment in relapsed multiple myeloma by Christian Taverna, Jérôme Voegeli, Andreas Trojan, Robert A Olie, Albert von Rohr

    Published 2012-04-01
    Get full text
    Article
  6. 6
    An immunocompetent patient with a recurrence-free Epstein-Barr virus positive plasmacytoma possesses robust Epstein-Barr virus specific T-cell responses

    An immunocompetent patient with a recurrence-free Epstein-Barr virus positive plasmacytoma possesses robust Epstein-Barr virus specific T-cell responses by Bithi Chatterjee, Laura Sahli, Obinna Chijioke, Philip Went, Christian Münz, Andreas Trojan

    Published 2017-10-01
    Get full text
    Article
  7. 7
    Biomarker dynamics and prognosis in breast cancer after neoadjuvant chemotherapy

    Biomarker dynamics and prognosis in breast cancer after neoadjuvant chemotherapy by Cristina Zarotti, Bärbel Papassotiropoulos, Constanze Elfgen, Konstantin Dedes, Denise Vorburger, Bernhard Pestalozzi, Andreas Trojan, Zsuzsanna Varga

    Published 2022-01-01
    Get full text
    Article
  8. 8
    Metastatic Salivary Duct Carcinoma with ERBB2 Amplification and Sequential Response to Ado-Trastuzumab Emtansine and Neratinib: A Case Report

    Metastatic Salivary Duct Carcinoma with ERBB2 Amplification and Sequential Response to Ado-Trastuzumab Emtansine and Neratinib: A Case Report by Nora Asper, Kersten Sven Roth, Thomas Frank Hany, Sacha Pierre Salzberg, Marianne Tinguely, Yannick Kadvany, Andreas Trojan

    Published 2023-11-01
    Get full text
    Article
  9. 9
    The Effect of Collaborative Reviews of Electronic Patient-Reported Outcomes on the Congruence of Patient- and Clinician-Reported Toxicity in Cancer Patients Receiving Systemic Therapy: Prospective, Multicenter, Observational Clinical Trial

    The Effect of Collaborative Reviews of Electronic Patient-Reported Outcomes on the Congruence of Patient- and Clinician-Reported Toxicity in Cancer Patients Receiving Systemic Ther... by Andreas Trojan, Nicolas Leuthold, Christoph Thomssen, Achim Rody, Thomas Winder, Andreas Jakob, Claudine Egger, Ulrike Held, Christian Jackisch

    Published 2021-08-01
    Get full text
    Article
  10. 10
    HER2/CEP17 Ratios and Clinical Outcome in HER2-Positive Early Breast Cancer Undergoing Trastuzumab-Containing Therapy.

    HER2/CEP17 Ratios and Clinical Outcome in HER2-Positive Early Breast Cancer Undergoing Trastuzumab-Containing Therapy. by Albina Stocker, Marie-Luise Hilbers, Claire Gauthier, Josias Grogg, Gerd A Kullak-Ublick, Burkhardt Seifert, Zsuzsanna Varga, Andreas Trojan

    Published 2016-01-01
    Get full text
    Article
  11. 11
    Correction: Comparison of EndoPredict and Oncotype DX Test Results in Hormone Receptor Positive Invasive Breast Cancer.

    Correction: Comparison of EndoPredict and Oncotype DX Test Results in Hormone Receptor Positive Invasive Breast Cancer. by Zsuzsanna Varga, Peter Sinn, Florian Fritzsche, Arthur von Hochstetter, Aurelia Noske, Peter Schraml, Christoph Tausch, Andreas Trojan, Holger Moch

    Published 2013-01-01
    Get full text
    Article
  12. 12
    Comparison of EndoPredict and Oncotype DX test results in hormone receptor positive invasive breast cancer.

    Comparison of EndoPredict and Oncotype DX test results in hormone receptor positive invasive breast cancer. by Zsuzsanna Varga, Peter Sinn, Florian Fritzsche, Arthur von Hochstetter, Aurelia Noske, Peter Schraml, Christoph Tausch, Andreas Trojan, Holger Moch

    Published 2013-01-01
    Get full text
    Article
  13. 13
    Impact of Electronic Patient-Reported Outcomes on Unplanned Consultations and Hospitalizations in Patients With Cancer Undergoing Systemic Therapy: Results of a Patient-Reported Outcome Study Compared With Matched Retrospective Data

    Impact of Electronic Patient-Reported Outcomes on Unplanned Consultations and Hospitalizations in Patients With Cancer Undergoing Systemic Therapy: Results of a Patient-Reported Ou... by Andreas Trojan, Christian Kühne, Michael Kiessling, Johannes Schumacher, Stefan Dröse, Christian Singer, Christian Jackisch, Christoph Thomssen, Gerd A Kullak-Ublick

    Published 2024-05-01
    Get full text
    Article
  14. 14
    Comparison of the Real-World Reporting of Symptoms and Well-Being for the HER2-Directed Trastuzumab Biosimilar Ogivri With Registry Data for Herceptin in the Treatment of Breast Cancer: Prospective Observational Study (OGIPRO) of Electronic Patient-Reported Outcomes

    Comparison of the Real-World Reporting of Symptoms and Well-Being for the HER2-Directed Trastuzumab Biosimilar Ogivri With Registry Data for Herceptin in the Treatment of Breast Ca... by Andreas Trojan, Sven Roth, Ziad Atassi, Michael Kiessling, Reinhard Zenhaeusern, Yannick Kadvany, Johannes Schumacher, Gerd A Kullak-Ublick, Matti Aapro, Alexandru Eniu

    Published 2024-04-01
    Get full text
    Article
  15. 15
    SAKK 21/12: a phase II trial of transdermal CR1447 in breast cancer patients

    SAKK 21/12: a phase II trial of transdermal CR1447 in breast cancer patients by Marcus Vetter, Karin M Rothgiesser, Qiyu Li, Hanne Hawle, Wolfgang Schönfeld, Karin Ribi, Salome Riniker, Roger von Moos, Andreas Trojan, Elena Kralidis, Mathias Fehr, Andreas Müller, Beat Thürlimann

    Published 2023-01-01
    Get full text
    Article
  16. 16
    A multicenter phase II trial (SAKK 36/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma

    A multicenter phase II trial (SAKK 36/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma by Christoph Renner, Pier Luigi Zinzani, Rémy Gressin, Dirk Klingbiel, Pierre-Yves Dietrich, Felicitas Hitz, Mario Bargetzi, Walter Mingrone, Giovanni Martinelli, Andreas Trojan, Krimo Bouabdallah, Andreas Lohri, Emmanuel Gyan, Christine Biaggi, Sergio Cogliatti, Francesco Bertoni, Michele Ghielmini, Peter Brauchli, Nicolas Ketterer

    Published 2012-07-01
    Get full text
    Article

Search Tools: